Authors
Karthi Duraisamy, Omayma Dlimi, Amine Bourzam, Benjamin Lefranc, Marie-Anne Le Solliec, Marie Picot, Nicolas Chartrel, Jean A Boutin, Olfa Masmoudi, Sergueï O Fetissov, Gaëtan Prévost, Jérôme Leprince
Published in
Obesity reviews : an official journal of the International Association for the Study of Obesity. Nov 16, 2026. Epub Nov 16, 2026.
Abstract
Obesity is a complex global health issue characterized by an imbalance in energy homeostasis and associated with significant health risks, including cardiovascular diseases, diabetes, and cancer. While various therapeutic approaches exist, peptide-based treatments have emerged as promising candidates due to their specificity and reduced side effects. Because many of the mechanisms are centrally regulated in the brain, effective intervention requires peptides with good brain penetration or alternative delivery strategies. In this context, this review explores the potential of intranasal delivery of therapeutic peptide candidates for obesity management, highlighting its advantages in bypassing the blood-brain barrier, targeting central pathways regulating appetite and energy expenditure, and minimizing systemic exposure, while also considering the translational limitations of this delivery route. The review analyses established and emerging peptides, including leptin, GLP-1 analogs, and oxytocin, focusing on their central mechanisms of action, specifically their ability to target the brain. It highlights how these peptides regulate energy homeostasis, appetite, and metabolism through direct activation of neural circuits in the hypothalamus, brainstem, and other key regions involved in obesity management. Furthermore, it evaluates the prospects of intranasal peptide therapeutics as an innovative strategy in obesity treatment, addressing both the opportunities and limitations in the context of clinical and preclinical evidence. Continued research and technological advancements are essential to optimize peptide formulations and delivery systems, ensuring efficacy, safety, and patient compliance in combating the obesity epidemic.
PMID:
43039358
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0